OTX-TKI (axitinib implant)

Phase 3

Ocular Therapeutix, Inc. (OCUL)

00%

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

3mo

OCUL⭐Phase 3$1.1B

OTX-TKI (axitinib implant) Phase 3 Results Expected

OTX-TKI (axitinib implant)• Neovascular Age-Related Macular Degeneration344

Apr 29

CT.gov

00%

Drug Information

Target Indication

Neovascular Age-Related Macular Degeneration

Clinical Trial

NCT06223958

Last updated: 12/4/2025

Regulatory Approvals

EMA9/19/2024

Axitinib Accord

Axitinib Accord is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.

View on EMA

EMA9/3/2012

Inlyta

Inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.

View on EMA

Developer

OCUL

Ocular Therapeutix, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

Ophthalmic InsertPhase 3

Open Angle Glaucoma and Ocular Hypertension

Punctum PlugPhase 3

Post Ocular Surgical Inflammation and Pain

DexamethasonePhase 3

Post-Surgical Ocular Pain

Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24Phase 3

Non-Proliferative Diabetic Retinopathy

Dextenza Ophthalmic InsertPhase 3

Cataract

View full pipeline